Classical Hodgkin Lymphoma
60
10
20
21
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
14 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.7%
7 terminated out of 60 trials
75.0%
-11.6% vs benchmark
7%
4 trials in Phase 3/4
67%
14 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (60)
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Itacitinib + Everolimus in Hodgkin Lymphoma
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
Phase Ib of L-NMMA and Pembrolizumab
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma